drug · small molecule
cannabidiol
Marketedupdated 3mo agoby $JAZZ Jazz Pharmaceuticals plc🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 82 investigational indications.
indications
investigational
EpilepsySchizophrenia
targets
Cannabinoid receptor 1
all catalysts(0)
nothing on the calendar yet
Trials studying cannabidiol
- phase4Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
- phase3Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
- phase2Unique Treatment of Oncology Pain in Advanced Cancer
- —Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
- phase2Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis
- phase4A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex
- phase4A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
- phase3Stratification and Treatment in Early Psychosis Study - PROMOTE
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 20, 2026
62 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (32)
- Mar 1, 2041method-of-use (U-3233)US 11160795
- Mar 1, 2041method-of-use (U-3233)US 11406623
- Mar 1, 2041method-of-use (U-3233)US 12102619
- Apr 26, 2039compositionUS 11207292
- Apr 26, 2039compositionUS 11865102
- Oct 13, 2035method-of-use (U-3073)US 10918608
- Oct 13, 2035method-of-use (U-3071)US 11065209
- Oct 13, 2035compositionUS 11096905
- Oct 13, 2035method-of-use (U-3071)US 11400055
- Jun 17, 2035method-of-use (U-2427)US 10092525
- Jun 17, 2035method-of-use (U-2442)US 10111840
- Jun 17, 2035method-of-use (U-2455)US 10137095
- Jun 17, 2035method-of-use (U-2783)US 10603288
- Jun 17, 2035method-of-use (U-2862)US 10709671
- Jun 17, 2035formulationUS 10709673
- Jun 17, 2035method-of-use (U-2780)US 10709674
- Jun 17, 2035method-of-use (U-2454)US 10849860
- Jun 17, 2035formulationUS 10966939
- Jun 17, 2035method-of-use (U-3236)US 11154516
- Jun 17, 2035method-of-use (U-3376)US 11311498
- Jun 17, 2035method-of-use (U-2862)US 11357741
- Jun 17, 2035method-of-use (U-3071)US 11446258
- Jun 17, 2035formulationUS 11633369
- Jun 17, 2035method-of-use (U-2781)US 11701330
- Jun 17, 2035method-of-use (U-2781)US 11766411
- Jun 17, 2035method-of-use (U-2781)US 11963937
- Jun 17, 2035method-of-use (U-3989)US 12064399
- Jun 17, 2035method-of-use (U-2421)US 9949937
- Jun 17, 2035method-of-use (U-2423)US 9956183
- Jun 17, 2035method-of-use (U-2424)US 9956184
- Jun 17, 2035method-of-use (U-2425)US 9956185
- Jun 17, 2035method-of-use (U-2426)US 9956186
FDA exclusivities (3)
- Jul 31, 2027ODE-326Orphan Drug (7y)346d
- Jul 31, 2027ODE-332Orphan Drug (7y)346d
- Oct 20, 2026M-270Method (3y)62d
News(3)
- Jazz to buy rare epilepsy drugmaker in potentially $1.3B dealActio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.biopharma_dive · 7d ago
- Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipelineJazz Pharmaceuticals is reaching into its wallet once again, this time buying Actio Biosciences and an experimental therapy for KCNT1+ epilepsy, a form of the disease with no FDA-approved treatments.biospace · 7d ago
- Jazz pays $820M to buy Actio, adding clinical-stage asset to orchestra of epilepsy therapiesJazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.fiercebiotech · 8d ago
Data sources
last refreshed 13m ago
Found something off?
comments(0)
5-min edit window · permanent after that